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Mutations in SLC26A1 Cause Nephrolithiasis
Heon Yung Gee,1,2,10 Ikhyun Jun,1,3,10 Daniela A. Braun,2 Jennifer A. Lawson,2 Jan Halbritter,2,4
Shirlee Shril,2 Caleb P. Nelson,5 Weizhen Tan,2 Deborah Stein,2 Ari J. Wassner,6 Michael A. Ferguson,2
Zoran Gucev,7 John A. Sayer,8 Danko Milosevic,9 Michelle Baum,2 Velibor Tasic,7 Min Goo Lee,1,*
and Friedhelm Hildebrandt2,*
Nephrolithiasis, a condition in which urinary supersaturation leads to stone formation in the urinary system, affects about 5%–10% of
individuals worldwide at some point in their lifetime and results in significant medical costs and morbidity. To date, mutations in more
than 30 genes have been described as being associated with nephrolithiasis, and these mutations explain about 15% of kidney stone
cases, suggesting that additional nephrolithiasis-associated genes remain to be discovered. To identify additional genes whosemutations
are linked to nephrolithiasis, we performed targeted next-generation sequencing of 18 hypothesized candidate genes in 348 unrelated
individuals with kidney stones. We detected biallelic mutations in SLC26A1 (solute carrier family 26 member 1) in two unrelated indi-
viduals with calcium oxalate kidney stones. We show by immunofluorescence, immunoblotting, and glycosylation analysis that the
variant protein mimicking p.Thr185Met has defects in protein folding or trafficking. In addition, by measuring anion exchange activity
of SLC26A1, we demonstrate that all the identified mutations in SLC26A1 result in decreased transporter activity. Our data identify
SLC26A1 mutations as causing a recessive Mendelian form of nephrolithiasis.Nephrolithiasis (MIM: 167030) is a major health problem
given that it affects up to 10% of the population in West-
ern countries. Its prevalence has significantly increased
among children over the last decades.1,2 This leads to
significant medical cost due to expensive surgical interven-
tions, progression to chronic kidney disease, and addi-
tional morbidity from renal colic and secondary urinary
tract infeciton.3 The formation of kidney stones is multi-
factorial, resulting from an interaction of environmental,
dietary, and genetic factors. Nephrolithiasis is genetically
heterogenous, and mutations in at least 30 genes have
been linked to this disorder.4,5 We recently demonstrated
in a cohort of 166 adults and 106 children with nephroli-
thiasis or nephrocalcinosis that a monogenic cause can
be detected in the surprisingly high percentage of 11.4%
of adult cases and 20.8% of childhood-onset cases.6 In a
follow-up study, we detected causative mutations in 1 of
30 linked genes in 16.7% of 143 individuals who mani-
fested with nephrolithiasis or nephrocalcinosis before 18
years of age.7 Both studies thus demonstrated a high per-
centage of individuals with a monogenic mutation associ-
ated with kidney stone formation. However, genetic
factors have been suggested to account for nearly 50% of
nephrolithiasis cases,8,9 indicating that additional nephro-
lithiasis-associated genes remain to be discovered.
To identify additional genes mutated in nephrolithiasis,
we generated a list of 18 hypothetical candidate genes and
performed exon amplification with consecutive next-gen-1Department of Pharmacology, Brain Korea 21 PLUS Project for Medical Scien
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 2016 American Society of Human Genetics.eration sequencing in a multicenter cohort of 348 individ-
uals with nephrolithiasis or isolated nephrocalcinosis.10
The cohorts were previously described, and consisted of
201 children and 147 adults who had at least one urinary
stone or nephrocalcinosis.6,7 For exclusion of known ge-
netic causes of nephrolithiasis, 30 genes previously linked
to nephrolithiasis were screened by exon sequencing in
these individuals, but no causative mutations were de-
tected. Written informed consent was obtained from all in-
dividuals enrolled in this study, and approval for human
subject researchwas obtained from the institutional review
boards at the Boston Children’s Hospital. The candidate
genes screened in this study are listed in Table S1. We de-
signed 210 target-specific primer pairs for coding exons
and the adjacent splice site of 18 genes. Amplicon sizes
were chosen to range from 250 to 300 base pairs. We
achieved a median sequencing coverage of 1983 per indi-
vidual and 1923 per amplicon. Only 9/350 (2.5%) individ-
uals had a median coverage below 20.
In an individual of Macedonian descent (A3054-21) who
is from non-consanguineous parents and clinically pre-
sented with acute renal failure due to bilateral obstructive
calculi, nephrocalcinosis, and bilateral ureteropelvic junc-
tion obstruction (UPJO), we detected two compound-het-
erozygous mutations in SLC26A1 (solute carrier family 26
member 1 [GenBank: NM_022042.3] [MIM: 610130])
(Table 1, Figure 1, and Figure S1). This individual had acute
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The Americage of five. He had recurrent episodes of renal colic due to
calcium oxalate nephrolithiasis and hypocitraturia and un-
derwent surgery for UPJO. The analysis of 24 hr urine
showed that this individual also had hyperoxaluria; other-
wise, urine and blood chemistries were normal (Table S2).
The two compound heterozygous missense mutations
(c.554C>T, p.Thr185Met and c.1073C>T, p.Ser358Leu)
in SLC26A1 are reported as SNPs in the dbSNP database;
however, their minor allele frequencies are below 0.0006
and they never occurred in a homozygous state (Table 1).
The amino acid residues affected by two missense muta-
tions were conserved throughout evolution down toDanio
rerio (Table 1 and Figure 1). Because this individual had
UPJO, we therefore performed whole-exome sequencing
(WES) and examined variants in genes associated with
congenital anomalies of the kidney and urinary tract
(CAKUT) or UPJO. However, we could not detect any addi-
tional pathogenic variants in these genes. In addition, we
examined genomic structural abnormality by using WES
data, but no structural variation was detected.
In a European-American boy (B641-12) who had neph-
rolithiasis and was born to consanguineous parents, we
detected a homozygous missense mutation in SLC26A1
(Table 1, Figure 1, and Figure S1). The paternal grandfather
of this individual also had nephrolithiasis. A kidney stone
was initially found in this individual during a computer-
ized tomography scan, which was performed for the eval-
uation of abdominal pain. In a 24 hr urine test, oxalate
was within normal range (Table S2). Renal function of
this individual was normal. The detected missense muta-
tion (c.166G>A, p.Ala56Thr) is reported as a SNP in the
dbSNP database; however, its minor allele frequency is
0.0002 and it never occurred in a homozygous state
(Table 1). Murine SLC26A1 has Ala at the position corre-
sponding to amino acid position 56 of human SLC26A1,
whereas the protein from Xenopus tropicalis or Danio rerio
has Val, which is also chemically related as a non-charged
non-polar residue (Table 1 and Figure 1).
SLC26A1 (also known as SAT1) was cloned as a sulfate
transporter from liver.11 It was subsequently characterized
as an anion exchanger that transports anions by media-
ting electroneutral sulfate-oxalate, sulfate-bicarbonate, or
oxalate-bicarbonate exchange.12,13 The Slc26a1/ mice
exhibit hyposulfatemia, hypersulfaturia, calcium oxalate
urolithiasis, and nephrocalcinosis in the setting of hyper-
oxalemia and hyperoxaluria.14 Slc26a1/ mice also show
infiltration of leukocytes around renal cortical vessels, sug-
gestive of UPJO.14 In this regard, it is of note that one of
the individuals with SLC26A1 mutations (A3054-21) had
UPJO, which could be based on a pathogenesis similar to
the one described in the murine model. In addition,
Slc26a1/ mice show enhanced drug-induced liver
toxicity, which might reflect reduced availability of intra-
cellular sulfate ion for drug conjugation reactions.14 These
findings demonstrate that, in mammals, SLC26A1 plays a
critical role in oxalate and sulfate homeostasis, which is
thought to be associated with kidney stone disease.an Journal of Human Genetics 98, 1228–1234, June 2, 2016 1229
Figure 1. Identification of Recessive
SLC26A1 Mutations in Two Individuals
with Nephrolithiasis
(A and B) Renal sonography of individuals
A3054-21 (A) and B641-12 (B) reveals kid-
ney stones.
(C) Exon structure of human SLC26A1
cDNA. SLC26A1 contains three exons. Po-
sitions of the start codon (ATG) and stop
codon (TAG) are indicated.
(D) Domain structure of SLC26A1. The
transmembrane (orange) and sulfate trans-
porter and AntiSigma factor antagonist
(STAS) domains are depicted by colored
bars, in relation to encoding exon posi-
tion. SLC26A1 has two N-linked glycosyla-
tion sites (amino acid positions 158 and
163, red lines). Three homozygous or com-
pound-heterozygous SLC26A1 mutations
detected in two families with nephrolithia-
sis are shown. Family numbers (under-
lined), mutations, and predicted transla-
tional changes are indicated (see Table 1).
(E) A partial protein alignment of SLC26A1
shows evolutionary conservation of the
identified missense changes.However, to date, the contribution of genetic variants in
SLC26A1 to nephrolithiasis in human is unknown. Daw-
son et al. examined SLC26A1 in 13 individuals with
recurrent calcium oxalate urolithiasis,15 but they were
unable to detect any biallelic mutations in SLC26A1. The
c.1667A>G, p.Gln556Arg variant, which was found in 6
out of 13 individuals examined, including one homozy-
gous individual, is a known SNP (rs3706622), and its allele
frequency is 0.6737 (26,773 homozygotes out of 79,535
individuals are reported in the Exome Aggregation Con-
sortium [ExAC] Browser), suggesting that this SNP is prob-
ably benign, rather than disease causing.
The SLC26A1 transporter is known to localize at the ba-
solateral membrane of renal proximal tubular epithelial
cells and enterocytes, as well as at the sinusoidal mem-
brane of hepatocytes.14,16,17 We confirmed by immunoflu-
orescence the localization of SLC26A1 in the rat kidney
and intestine (Figure 2). We show that SLC26A1 is present
in the basolateral membrane of peanut lectin-positive
proximal tubules in the renal cortex and basolaterally in
the AQP2-positive principle cells, as well as the AQP2-1230 The American Journal of Human Genetics 98, 1228–1234, June 2, 2016negative intercalated cells of collect-
ing ducts in the medulla (Figures 2A
and 2B). SLC26A1 also localizes to
cytoplasm and basolateral mem-
branes of the ileum and colon
(Figure 2C and 2D).
To evaluate the impact of the iden-
tified human mutations on SLC26A1
function, we performed immunofluo-
rescence in HEK293T cells upon over-
expression of wild-type (WT) and
mutant SLC26A1s. A mouse Slc26a1clone was purchased from Open Biosystems (clone acces-
sion no. BC025824), and mutant clones of Slc26a1 were
generated by PCR-based site-directed mutagenesis. The
WT protein and the variant protein harboring p.Ala56Thr
localized to plasma membranes (Figure 2E), whereas the
p.Thr190Met variant (which corresponds to p.Thr185Met
in human protein) failed to reach the plasma membrane
and was trapped in the endoplasmic reticulum (ER) as
shown by colocalizationwith an ERmarker, BiP (Figure 2E).
The SLC26A1 variant harboring p.Ser363Leu, which corre-
sponds to p.Ser358Leu in human protein, reached the cell
surface; however, a significant portion of protein was trap-
ped in the ER, suggesting a processing defect (Figure 2E).
The protein amounts of WT and variant SLC26A1s were
analyzed in HEK293T and also in PANC-1 cells (Figure 3).
Because PANC-1 cells derived from pancreatic ducts retain
epithelial properties and do not have endogenous
SLC26A1, they constitute a suitable model for studying
protein processing through transfection of plasmids en-
coding WT and variant SLC26A1s (Figure 3). SLC26A1 un-
dergoes the Golgi-mediated complex-glycosylation (band
Figure 2. Localization of SCL26A1 in the
Kidney and Intestine and the Effects of
SLC26A1 Mutation on Subcellular Locali-
zation of SLC26A1
(A and B) Localization of SLC26A1 in the
renal cortex (A) and medulla (B). Rat kid-
ney sections were immunostained with
fluorescein isothiocyanate-labeled peanut
lection (PNA) for proximal tubules, anti-
SLC26A1 (rabbit polyclonal, Novus Biolog-
ical, 1:200), and anti-aquaporin 2 (AQP2,
mouse monoclonal, Santa Cruz Biotech-
nology, 1:100) for principal cells of collect-
ing ducts antibodies. In the renal cortex,
SLC26A1 (red) mainly localized to prox-
imal tubules, which were marked green
by PNA (A). In the medulla, SLC26A1
(red) was present in collecting duct princi-
ple cells (arrowheads), which were marked
apically blue-green by AQP2, but also in
intercalated cells (arrows), which were
not marked by AQP2 (23 for inset) (B).
(C and D) Localization of SLC26A1 in the
ileum (C) and colon (D). Intestines from
rat were immunostained with anti-E-cad-
herin (mousemonoclonal,BDTransduction
Laboratories, 1:100), anti-SLC26A1, and
anti-Zona Occuldnes-1 (ZO-1, goat poly-
clonal, Santa Cruz Biotechnology, 1:100)
antibodies. E-cadherin and ZO-1 mark
adherens and tight junctions, respectively.
(E) Immunofluorescence of WT and
variant proteins of SLC26A1 in HEK293T
cells. HEK293T cells were transfected with
N-terminally Myc-tagged WT Slc26a1 or
mutant clones. Cells were fixed and
permeabilized with methanol and immu-
nostained with anti-Myc (mouse mono-
clonal, Cell Signaling Technology, 1:200),
anti-BiP (rabbit polyclonal, Abcam,
1:100), and anti-GOLGBP1 (rabbit polyco-
lonal, Sigma, 1:100) antibodies. BiP and
GOLGBP1 mark the endoplasmic reticu-
lum and Golgi apparatus, respectively.C) after an initial core-glycosylation at the ER (band B). In
general, the Golgi-glycosylated forms of SLC26A1 are pre-
sent at the cell surface. When we examined the protein
amounts of variant proteins, we found them significantly
reduced, as compared to WT proteins (Figures 3A and
3D). SLC26A1 p.Thr190Met in particular was not pro-
cessed to the fully glycosylated form (Figures 3A and 3D),
which suggests that the p.Thr190Met protein is degraded
via the ER-associated protein degradation (ERAD) pathway
and is consistent with the finding that the p.Thr190Met
protein was not observed in the plasma membrane
(Figure 2E).
To confirm whether the lower band of SLC26A1 in
immunoblotting truly represented the ER form, we treated
the protein samples of WT SLC26A1 and the p.Thr190Met
variant with endoglycosidase H (Endo H) and peptide-
N-glycosidase F (PNGase F) (Figures 3B and 3E). The
band size of Endo-H-treated WT sample did not change
(band C), whereas the band size of the PNGase-F-treated
sample decreased to that of the p.Thr190Met variant pro-The Americtein. On the other hand, the band size of the Endo-
H-treated p.Thr190Met variant protein (band B) decreased
to that of PNGase-F-treated WT or p.Thr190Met
SLC26A1 (band A). The Endo-H-sensitive digestion of the
p.Thr190Met protein suggests that this variant protein ex-
ists as an ER form (band B). We performed real-time PCR
experiments to determine whether the reduced amounts
of variant proteins were due to a reduced number of tran-
scripts or to poor protein stability. We found that the num-
ber of transcripts of Slc26a1 was not significantly different
in cells transfected with WT and mutant plasmids
(Figure S2), indicating that mRNA of WT Slc26a1 and
mRNAs harboring mutations are not different at the tran-
scription level. These results also indicate that reduced
amounts of the p.Ser363Leu variant protein is associated
with deficient protein stability.
To verify functional abnormalities of SLC26A1 variant
proteins, we measured the anion transporting activity
of SLC26A1 by monitoring intracellular pH (pHi) in
HEK293T cells after transfection with Slc26a1 plasmidsan Journal of Human Genetics 98, 1228–1234, June 2, 2016 1231
Figure 3. Immunoblotting and Real-
Time PCR Assay of Wild-Type and Variant
SLC26A1 Proteins
(A) HEK293T cells were transfected with
Slc26a1 WT and mutant plasmids, and
immunoblotting assays of SLC26A1 were
performed. Cells were harvested, and the
protein samples were separated by SDS-
polyacrylamid gel electrophoresis. The
separated proteins were transferred to a
nitrocellulose membrane and blotted
with appropriate primary and secondary
antibodies. Anti-Myc (mouse monoclonal,
Santa Cruz Biotechnology, 1:1000) anti-
body was used as primary antibody, and
anti-Mouse IgG (HRP) (Thermo Scientific)
antibody was used as secondary antibody.
Protein bands were detected by enhanced
chemiluminescence (Amersham Biosci-
ences). Due to higher protein amounts of
the WT SLC26A1 and p.Ala56Thr variant
than of the p.Thr190Met or p.Ser363Leu
variants, one-fifth of protein sample was
used for WT SLC26A1 and the p.Ala56Thr
variant.
(B) Samples from cells expressing WT-
or p.Thr190Met-SLC26A1 were digested
with endoglycosidase H (Endo H, New
England Biolabs) and peptide N-glycosi-
dase F (PNGase F), according to the manu-
facturer’s instructions. In the WT protein,
complex glycosylated form, band C was
not shifted after treatment of Endo H and
was shifted to band A after treatment of
PNGase F. In the p.Thr190Met variant, core glycosylated form, band B is dominant and was shifted to band A after treatment with
Endo H. The p.Thr190Met variant is degraded by the ER-associated degradation (ERAD) pathway.
(C) Relative protein amounts of band C of SLC26A1 variants in HEK293T cells. All variants showed lower protein amounts than the WT
protein.
(D) Immunoblotting assays of SLC26A1 in PANC-1 cells. The results were comparable with those in HEK293T cells.
(E) Treatment of glycosidase in PANC-1 cells showed a similar effect to that seen in HEK293T cells.
(F) Relative protein amounts of band C of SLC26A1 variants in PANC-1 cells.(Figure 4). We measured pHi with a pH-sensitive fluores-
cent probe, 20,70-Bis(2-carboxyethyl)-5(6)-carboxyfluores-
cein acetoxymethyl ester (BCECF-AM), as described previ-
ously.18 Previous studies have revealed that SLC26A1
can transport chloride, bicarbonate, oxalate, and sul-
fate.12,19,20 Although SLC26A1 also has HCO3
-oxalate
exchange activities (Figure S3), we instead analyzed
SLC26A1-mediated SO4
2-HCO3
 exchange activities
because of a technical advantage allowing us to observe
more robust pHi changes in these activities (Figure 4). We
first loaded HEK293T cells with HCO3
 by using endoge-
nous Cli-HCO3

o exchange activities. Then, we analyzed
the initial rate of pHi reduction due to HCO3

i-SO4
2
o ex-
change activities after challenging the cells with 25 mM
SO4
2. As shown in Figures 4A and 4B, cells expressing
SLC26A1, but not mock-transfected cells, showed a
strong HCO3
-SO4
2 exchange activity. Subsequently, we
measured the transport activities of SLC26A1 variant pro-
teins in the same manner. Compared to WT SLC26A1, all
the variants showed decreased HCO3
-SO4
2 exchange ac-
tivities (Figures 4B–4E), especially the folding defect
mutant, p.Thr190Met, for which activity almost vanished1232 The American Journal of Human Genetics 98, 1228–1234, June(Figure 4D). The summaries of difference and slope of
intracellular pH are given in Figure 4F.
Here, using a candidate gene approach, we demonstrate
that mutations in SLC26A1 cause an autosomal-recessive
form of calcium oxalate nephrolithiasis. Our functional
studies indicate that all the identified mutations in
SLC26A1 lead to decreased transporter activity. Hyperoxa-
lemia in Slc26a1/micewasmost likely caused by reduced
intestinal secretion of oxalate, based on reduced oxalate
transport in basolateral membrane vesicles from the distal
ileum, cecum, and proximal colon, as well as decreased
cecal oxalate content. Hyperoxalemia led to hyperoxaluria
and calcium oxalate nephrolithiasis. Similarly, reduced in-
testinal secretion of oxalate, which resulted from decreased
transporter activity, probably led to calcium oxalate stones
in individuals with SLC26A1 mutations. Slc26a1/ mice
have increased liver sensitivity to acetaminophen.14
Administration of acetaminophen led to a 4-fold increase
in serum alanine transaminase levels and extensive liver
necrosis in Slc26a1/ mice.14 Therefore, it will be of high
clinical relevance to determine whether individuals with
biallelic mutations in SLC26A1 also exhibit drug-induced2, 2016
Figure 4. Measurement of HCO3
-sul-
fate exchange activity
Measurements of pHi in transfected
HEK293T cells were performed with the
pH-sensitive fluorescent probe BCECF
with co-transfection of the trans-gene
marker pEGFP-N1 (Life Technologies). We
recorded BCECF fluorescence at the excita-
tion wavelengths of 490 and 440 nm at a
resolution of 2/s by using a recording
setup (Delta Ram; PTI). Removal of Cl
from the bath solution induced intracel-
lular accumulation of HCO3
 (increase
in pHi) as a result of endogenous Cli-
HCO3

o exchange activities. Then, addi-
tion of 25 mM SO4
2 to the bath solution
evoked a reduction in pHi as a result of
HCO3

i-SO4
2
o exchange activities. All ex-
periments were performed at 37C.
(A–E) Representative traces of HEK293T
cells expressing EGFP alone (A) and WT
(B), p.Ala56Thr (C), p.Thr190Met (D),
and p.Ser363Leu (E) SLC26A1 proteins.
(F) Summaries of HCO3
-sulfate exchange
activity. The intrinsic buffer capacity of
HEK293T cells was 10.05 mM per pH unit
(at pHi 7.0), and this value was not signifi-
cantly different for cells transfected with
WT or variant Slc26a1. Therefore, the
HCO3
-SO4
2 exchange activities were
presented as DpH unit per min without
compensating for the buffer capacity.
Data are presented as mean 5 SEM. *p <
0.05, **p < 0.01.hepatotoxicity. According to the findings in Slc26a1/
mice, acetaminophenmight be contraindicated in individ-
uals with SLC26A1mutations.Supplemental Data
Supplemental Data include three figures and two tables and can be
found with this article online at http://dx.doi.org/10.1016/j.ajhg.
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